Interleukin-6 and rheumatic diseases

被引：88

作者：

Lipsky, Peter E. ^{[1
]}

机构：

[1] NIAMSD, Autoimmun Branch, NIH, Bethesda, MD 20892 USA

来源：

ARTHRITIS RESEARCH & THERAPY | 2006年 / 8卷 / Suppl 2期

关键词：

D O I：

10.1186/ar1918

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IL-6 is a pleiotropic cytokine involved in both the initiation and the maintenance of the inflammatory and immunologic responses in certain autoimmune diseases. Blocking of these two complementary functions of IL-6 may confer additive, or even unique, benefits to the patient. The levels of both IL-6 and its soluble receptor (slL-6R alpha) are elevated to various degrees in many rheumatic diseases. IL-6 blockade has been shown to be beneficial both in experimental models and in human disease, and inhibition of IL-6 signaling with a molecule such as tocilizumab could prevent or reverse some of the complications typically associated with rheumatic diseases.

引用

页数：5

共 39 条

[1] Interleukin 6 is required for the development of collagen-induced arthritis [J].

Alonzi, T ;

Fattori, E ;

Lazzaro, D ;

Costa, P ;

Probert, L ;

Kollias, G ;

De Benedetti, F ;

Poli, V ;

Ciliberto, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (04) :461-468

[2] Anemia of inflammation: the cytokine-hepcidin link [J].

Andrews, NC .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (09) :1251-1253

[3] Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women [J].

Bermudez, EA ;

Rifai, N ;

Buring, J ;

Manson, JE ;

Ridker, PA .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (10) :1668-1673

[4] Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipolysaccharide or IL-1 beta: A study on IL-6-deficient mice [J].

Chai, Z ;

Gatti, S ;

Toniatti, C ;

Poli, V ;

Bartfai, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (01) :311-316

[5] Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial [J].

Choy, EHS ;

Isenberg, DA ;

Garrood, T ;

Farrow, S ;

Ioannou, Y ;

Bird, H ;

Cheung, N ;

Williams, B ;

Hazleman, B ;

Price, R ;

Yoshizaki, K ;

Nishimoto, N ;

Kishimoto, T ;

Panayi, GS .

ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3143-3150

[6] BONE TURNOVER IN NONSTEROID TREATED RHEUMATOID-ARTHRITIS [J].

COMPSTON, JE ;

VEDI, S ;

CROUCHER, PI ;

GARRAHAN, NJ ;

OSULLIVAN, MM .

ANNALS OF THE RHEUMATIC DISEASES, 1994, 53 (03) :163-166

[7]

Desgeorges A, 1997, J RHEUMATOL, V24, P1510

[8]

Ding CH, 2003, CURR OPIN MOL THER, V5, P64

[9] Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly [J].

Harris, TB ;

Ferrucci, L ;

Tracy, RP ;

Corti, MC ;

Wacholder, S ;

Ettinger, WH ;

Heimovitz, H ;

Cohen, HJ ;

Wallace, R .

AMERICAN JOURNAL OF MEDICINE, 1999, 106 (05) :506-512

[10] Immune responses of IL-4, IL-5, IL-6 deficient mice [J].

Kopf, M ;

LeGros, G ;

Coyle, AJ ;

KoscoVilbois, M ;

Brombacher, F .

IMMUNOLOGICAL REVIEWS, 1995, 148 :45-69

← 1 2 3 4 →